Thrombolytic Science
TSI, a Cambridge-based biopharmaceutical firm, pioneers in thrombolytic research for clot treatment since 2006.
Founded
2004TSI, a Cambridge-based biopharmaceutical firm, pioneers in thrombolytic research for clot treatment since 2006.
Thrombolytic Science, LLC (TSI) is a private, clinical-stage biopharmaceutical company founded in 2006 by Harvard scientist Victor Gurewich and business person Alexis Wallace. Based in Cambridge, Massachusetts, TSI focuses on revolutionizing the treatment of ischemic stroke and heart attack through advanced thrombolytic research. The company's core mission is to re-establish blood flow faster and more safely, aiming to deliver treatments that can be administered in ambulances to minimize delays in care.
Notable figures associated with TSI include co-founder Victor Gurewich, whose research underpins the company's innovative approach. TSI has garnered attention for its pioneering work in sequential fibrinolysis, a method designed to break up blood clots more effectively without causing bleeding. The company's impact is evident in its potential to transform the standard of care for vascular emergencies, offering hope for faster, safer recovery for stroke and heart attack patients.
Companies similar to Thrombolytic Science include Thrombolex, Basking Biosciences, eXIthera Pharmaceuticals and CeleCor Therapeutics.
Thrombolytic Science was founded in 2004.
Thrombolytic Science's headquarters is located in Cambridge, MA, US.
Thrombolytic Science's most recent funding round was for $7.5M (USD) in January 2012.
As of Jan 12, 2012, Thrombolytic Science has disclosed funding of $7.5M (USD). Undisclosed round amounts are excluded.
Thrombolytic Science has 3 employees as of Feb 4, 2024.
CeleCor Therapeutics
celecor.com
